Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis

Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) mutation benefit from a first line of treatment with tyrosine kinase inhibitors (TKIs). After progression, the choice of treatment is between chemotherapy and immune checkpoint inhibitors, but the role of EGFR m...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavanna, Luigi, Citterio, Chiara, Orlandi, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349440/
https://www.ncbi.nlm.nih.gov/pubmed/30719215
http://dx.doi.org/10.18632/oncotarget.26541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349440/
https://www.ncbi.nlm.nih.gov/pubmed/30719215
http://dx.doi.org/10.18632/oncotarget.26541

Ejemplares similares